Abousamra Nashwa Khairat, Salah El-Din Manal, Hamza Elzahaf Eman, Esmael Mohammed Ebrahim
Department of Clinical Pathology, Hematology Unit, Faculty of Medicine, Mansoura University , Egypt.
Leuk Lymphoma. 2015 Jan;56(1):113-9. doi: 10.3109/10428194.2014.907893. Epub 2014 Jun 5.
Numerous prognostic markers were introduced to screen for patients with B-cell chronic lymphocytic leukemia (B-CLL) likely to have a progressive course, bearing the potential to facilitate risk-adapted treatment strategies. Extracellular adenosine triphosphate (ATP) functions as a "natural adjuvant" that boosts immune response in the tumor microenvironment. Ectonucleoside triphosphate diphosphohydrolase-1 (CD39/ENTPD1) is the ectonucleotidase that catalyzes the hydrolysis of ATP. The present study was conducted to analyze CD39 expression in T cells and B-CLL cells to evaluate its impact on the clinical course of patients with B-CLL and correlate its levels with well-established risk factors. T-cell CD39 expression was significantly increased in patients' peripheral blood compared to healthy controls. The higher levels were associated with advanced stages of disease and negatively interacted with time to first treatment. Overall, our data indicate that T-cell CD39 expression may identify subsets of patients with B-CLL with an unfavorable clinical outcome. Moreover, it can be incorporated into prognostic schema to improve the prediction of CLL disease progression.
引入了许多预后标志物来筛选可能有进展性病程的B细胞慢性淋巴细胞白血病（B-CLL）患者，有望促进风险适应性治疗策略。细胞外三磷酸腺苷（ATP）作为一种“天然佐剂”，可增强肿瘤微环境中的免疫反应。外核苷酸三磷酸二磷酸水解酶-1（CD39/ENTPD1）是催化ATP水解的外核苷酸酶。本研究旨在分析T细胞和B-CLL细胞中CD39的表达，以评估其对B-CLL患者临床病程的影响，并将其水平与已确立的危险因素相关联。与健康对照相比，患者外周血中T细胞CD39表达显著增加。较高水平与疾病晚期相关，并与首次治疗时间呈负相关。总体而言，我们的数据表明，T细胞CD39表达可能识别出临床结局不佳的B-CLL患者亚组。此外，它可纳入预后模式以改善对CLL疾病进展的预测。
